Clinical

Articles

The guidelines now include the use of piflufolastat F 18, along with all approved PSMA-PET imaging agents, for the selection of prostate cancer patients to receive PSMA-targeted radioligand therapy.

NCCN, SNMMI add piflufolastat F18 to guidelines for prostate cancer imaging

177Lu-PSMA-617 is FDA-approved for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer. 

177Lu-PSMA-617 production, trial enrollment temporarily suspended

The phase 2 STARLITE 2 trial is exploring the combination of the novel radiopharmaceutical TLX250 (177Lu-DOTA-girentuximab) and nivolumab in patients with advanced renal cell carcinoma.

Study launches of novel radiopharmaceutical TLX250 in kidney cancer

The ongoing phase 1/2 COBRA trial is exploring the PSMA-PET imaging agent 64Cu SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.

Treatment begins in trial of 64Cu SAR-bisPSMA in biochemically recurrent prostate cancer

Videos

“Overall, there's no known advantage or disadvantage in a head-to-head trial of either one of these, but I do think they're complementary,” says Scott T. Tagawa, MD, when discussing radium-223 dichloride and lutetium Lu 177 vipivotide tetraxetan. 

Dr. Tagawa on 2 radiopharmaceuticals for prostate cancer with a proven survival advantage

The novel radionuclide combination was safe and effective in men with progressive mCRPC who had previously received chemotherapy and novel androgen signaling inhibitors. 

Combo of 177Lu-PSMA-617 and novel radiosensitizer effective in mCRPC

"Tools such as Illuccix PSMA-PET are incredibly valuable as we look for better ways to manage prostate cancer in men," said Michael Koch, MD. 

First patient receives newly-approved PSMA-PET imaging product

"With the existing drugs, we are looking to make them better," said Scott T. Tagawa, MD. 

Dr. Tagawa recaps breakthroughs with therapeutic radiopharmaceuticals in prostate cancer

Richard Wahl, MD, president of the Society of Nuclear Medicine and Molecular Imaging, highlights the approval of 177Lu-PSMA-617 (Lu 177 vipivotide tetraxetan) as the first targeted radioligand therapy for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer.

Expert explains significance of FDA approval of 177Lu-PSMA-617 for mCRPC

Phillip S. Low, PhD, led research that was critical to the development of targeted radioligand therapy 177Lu-PSMA-617 for the treatment of patients with prostate cancer. 

Next-Generation Imaging